Physician profile
M O Dada
NPI 1881744878
$14,086.72
in general payments reported to CMS, 2019-2025
44 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $269 · 2021: $1,391 · 2022: $2,266 · 2023: $3,367 · 2024: $2,394 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,182 · Education: $75.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,182.49 |
| Education | $75.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,830.22 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Amgen INC. | $1,631.44 | 2019-2025 | Evenity, Repatha, Repatha |
| Abbvie INC. | $1,467.65 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $1,269.12 | 2019-2024 | Xarelto, Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $886.33 | 2021-2025 | |
| Novo Nordisk INC | $613.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $606.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $567.45 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $523.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.47 | 2023-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $291.75 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $279.83 | 2020-2023 | |
| Allergan, INC. | $255.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $245.24 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.12 | 2023-2024 | Xifaxan |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $179.69 | 2023 | Vumerity, Tysabri |
| Abbott Laboratories | $172.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pulmonx Corporation | $158.18 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Astellas Pharma US INC | $153.90 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $133.94 | 2022 | |
| Ardelyx, INC. | $133.59 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $124.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $120.54 | 2022 | |
| Alkermes, INC. | $99.54 | 2024 | Lybalvi |
| Novartis Pharmaceuticals Corporation | $85.79 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $77.26 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $74.76 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $68.77 | 2019-2024 | Gardasil 9, Capvaxive, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.10 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Actelion Pharmaceuticals US, INC. | $64.49 | 2023 | Uptravi, Opsumit |
| Verona Pharma, INC. | $50.64 | 2025 | Ohtuvayre |
| Organon LLC | $48.41 | 2021-2024 | |
| Abiomed | $35.97 | 2024 | Impella |
| Otsuka America Pharmaceutical, INC. | $34.32 | 2022 | |
| Boston Scientific Corporation | $22.58 | 2019 | |
| Inspire Medical Systems, INC. | $20.46 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $20.43 | 2023 | Inpefa |
| Ultragenyx Pharmaceutical INC. | $18.61 | 2023 | |
| Ironwood Pharmaceuticals, INC | $16.23 | 2020 | |
| Medtronic, INC. | $14.95 | 2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $13.75 | 2023 | Eliquis |
| Jazz Pharmaceuticals INC. | $13.28 | 2021 | |
| Eisai INC. | $11.52 | 2021 | |
| Melinta Therapeutics, LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.